瑞尼琳牌氨糖胶原蛋白胶囊 （Joint Enhancer）
产品简介
瑞尼琳牌氨糖胶原蛋白胶囊是一种有助于骨骼和关节健康的功能性保健食品。 UC-II®作为本产品的重要活性成分，是一种受国际专利保护的、天然的、非变性的II型胶原蛋白。它通过调节人体免疫系统实现改善关节的活动性，柔韧性，促进关节健康的作用。 UC-II®是组成软骨的主要结构蛋白，适合用于补充老年人和更年期妇女骨骼和关节中丢失的胶原蛋白。*
人体临床研究表明，每日仅40毫克的UC-II®可改善关节舒适性，柔韧性和灵活性。 最新的随机双盲研究表明，UC-II®在增加关节功能方面明显的比氨基葡萄糖+软骨素的联合效果更好。*
UC-II®是FDA批准的新膳食成分（NDI）。 UC-II®是未变性II型胶原蛋白的唯一来源。它也是美国哈佛大学类风湿病学教授 David.Trentham 博士用于临床研究的唯一胶原蛋白产品。他领导了II型胶原蛋白有效性的临床研究。
UC-II®以鸡胸骨软骨为原料，采用美国低温专利技术在美国GMP认证的工厂生产制造，确保产品中天然活性（未变性）II型胶原蛋白的含量。 UC-II®经过美国着名科学专家小组对产品的安全性和毒理学数据进行了全面审查，通过了美国Self-Affirmed GRAS认证，确认UC-II属于一般公认的安全膳食成分。
更多专业研究请参阅《临床研究》
- * 本声明未经美国食品药品管理局评估。 本产品不用于诊断，治疗或预防任何疾病。 本网站提供的信息仅供您一般参考，不能代替专业医疗建议或针对特定疾病的治疗。
临床研究
Here, you can read some of important published clinical research papers about UC-II, which support its efficacy on improving joint mobility and flexibility. Published peer reviewed studies can be accessed through PubMed at www.ncbi.nlm.nih.gov/pubmed. For more information, please contact 该邮件地址已受到反垃圾邮件插件保护。要显示它需要在浏览器中启用 JavaScript。.
UC-II Proven to be more effective than glucosamine & chondroitin for osteoarthritis
Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study
Abstract
Background: Undenatured type II collagen (UC-II) is a nutritional supplement derived from chicken sternum cartilage. The purpose of this study was to evaluate the efficacy and tolerability of UC-II for knee osteoarthritis (OA) pain and associated symptoms compared to placebo and to glucosamine hydrochloride plus chondroitin sulfate (GC).
Methods: One hundred ninety one volunteers were randomized into three groups receiving a daily dose of UC-II (40 mg), GC (1500 mg G & 1200 mg C), or placebo for a 180-day period. The primary endpoint was the change in total Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) from baseline through day 180 for the UC-II group versus placebo and GC. Secondary endpoints included the Lequesne Functional Index (LFI), the Visual Analog Scale (VAS) for pain and the WOMAC subscales. Modified intent-to-treat analysis were performed for all endpoints using analysis of covariance and mixed model repeated measures, while incremental area under the curve was calculated by the intent-to-treat method.
Results: At day 180, the UC-II group demonstrated a significant reduction in overall WOMAC score compared to placebo (p = 0.002) and GC (p = 0.04). Supplementation with UC-II also resulted in significant changes for all three WOMAC subscales: pain (p = 0.0003 vs. placebo; p = 0.016 vs. GC); stiffness (p = 0.004 vs. placebo; p=0.044 vs. GC); physical function (p = 0.007 vs. placebo). Safety outcomes did not differ among the groups.
Conclusion: UC-II improved knee joint symptoms in knee OA subjects and was well-tolerated. Additional studies that elucidate the mechanism for this supplement’s actions are warranted.
Source: Lugo et al. Nutrition Journal (2016) 15:14
Toxicological evaluation showed a broad-spectrum safety profile of UC-II
Safety and toxicological evaluation of undenatured type II collagen.
Abstract: Previous research has shown that undenatured type II collagen is effective in the treatment of arthritis. The present study evaluated the broad-spectrum safety of UC-II by a variety of toxicological assays including acute oral, acute dermal, primary dermal irritation, and primary eye irritation toxicity. In addition, genotoxicity studies such as Ames bacterial reverse mutation assay and mouse lymphoma tests, as well as a dose-dependent 90-day sub-chronic toxicity study were conducted. Safety studies indicated that acute oral LD(50) of UC-II was greater than 5000 mg/kg in female Sprague-Dawley rats. No changes in body weight or adverse effects were observed following necropsy. Acute dermal LD(50) of UC-II was determined to be greater than 2000 mg/kg. Primary skin irritation tests conducted on New Zealand Albino rabbits classified UC-II as slightly irritating. Primary eye irritation tests conducted on rabbits indicated that UC-II was moderately irritating to the eye. UC-II did not induce mutagenicity in the bacterial reverse mutation test in five Salmonella typhimurium strains either with or without metabolic activation. Similarly, UC-II did not induce a mutagenic effect in the gene mutation test in mouse lymphoma cells either with or without metabolic activation. A dose-dependent 90-day sub-chronic toxicity study revealed no pathologically significant changes in selected organ weights individually or as percentages of body or brain weights. No significant changes were observed in hematology and clinical chemistry. Therefore, the results from the current study show a broad-spectrum safety profile of UC-II.
Source: Toxicol Mech Methods. 2010 May;20(4):175-189.
Safety and efficacy of UC-II in the treatment of osteoarthritis of the knee
Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial
Abstract: Previous studies have shown that undenatured type II collagen (UC-II) is effective in the treatment of rheumatoid arthritis, and preliminary human and animal trials have shown it to be effective in treating osteoarthritis (OA). The present clinical trial evaluated the safety and efficacy of UC-II as compared to a combination of glucosamine and chondroitin (G+C) in the treatment of OA of the knee. The results indicate that UC-II treatment was more efficacious resulting in a significant reduction in all assessments from the baseline at 90 days; whereas, this effect was not observed in G+C treatment group. Specifically, although both treatments reduced the Western Ontario McMaster Osteoarthritis Index (WOMAC) score, treatment with UC-II reduced the WOMAC score by 33% as compared to 14% in G+C treated group after 90 days. Similar results were obtained for visual analog scale (VAS) scores. Although both the treatments reduced the VAS score, UC-II treatment decreased VAS score by 40% after 90 days as compared to 15.4% in G+C treated group. The Lequesne’s functional index was used to determine the effect of different treatments on pain during daily activities. Treatment with UC-II reduced Lequesne’s functional index score by 20% as compared to 6% in G+C treated group at the end of 90-day treatment. Thus, UC-II treated subjects showed significant enhancement in daily activities suggesting an improvement in their quality of life.
Source: Int.J.Med.Sci.2009; 6(6):312-321
Research data from Harvard shown efficacy of type II collagen in Rheumatoid Arthritis
Effects of oral administration of type II collagen on rheumatoid arthritis.
Abstract: Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.
Source: Science 24 September 1993:Vol. 261 no. 5129 pp. 1727-1730
Comparative efficacy of UC-II, glucosamine and chondroitin in arthritic animals
Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to
glucosamine and chondroitin in arthritic horses.
Abstract: The present investigation evaluated arthritic pain in horses receiving daily placebo, undenatured type II collagen (UC-II) at 320, 480, or 640 mg (providing 80, 120, and 160 mg active UC-II, respectively), and glucosamine and chondroitin (5.4 and 1.8 g, respectively, bid for the first month, and thereafter once daily) for 150 days. Horses were evaluated for overall pain, pain upon limb manipulation, physical examination, and liver and kidney functions. Evaluation of overall pain was based upon a consistent observation of all subjects during a walk and a trot in the same pattern on the same surface. Pain upon limb manipulation was conducted after the walk and trot. It consisted of placing the affected joint in severe flexion for a period of 60 sec. The limb was then placed to the ground and the animal trotted off. The response to the flexion test was then noted with the first couple of strides the animal took. Flexion test was consistent with determining clinically the degree of osteoarthritis in a joint. Horses receiving placebo showed no change in arthritic condition, while those receiving 320 or 480 or 640 mg UC-II exhibited significant reduction in arthritic pain (P < 0.05). UC-II at 480 or 640 mg dose provided equal effects, and therefore, 480 mg dose was considered optimal. With this dose, reduction in overall pain was from 5.7 ± 0.42 (100%) to 0.7 ± 0.42 (12%); and in pain upon limb manipulation from 2.35 ± 0.37 (100%) to 0.52 ± 0.18 (22%). Although glucosamine and chondroitin treated group showed significant (P < 0.05) reduction in pain compared with pretreated values, the efficacy was less compared with that observed with UC-II. In fact, UC-II at 480 or 640 mg dose was found to be more effective than glucosamine and chondroitin in arthritic horses. Clinical condition (body weight, body temperature, respiration rate, and pulse rate), and liver (bilirubin, GGT, and ALP) and kidney (BUN and creatinine) functions remained unchanged, suggesting that these supplements were well tolerated.
Source: J Vet Pharmacol Ther. 2009 Dec;32(6):577-84
精选问答
UC-II®是一种受美国、欧盟、日本和加拿大九项国际发明专利保护的，非变性（天然）II型胶原蛋白。UC-II®以鸡胸骨软骨为原料，采用美国专利技术在低温条件下萃取获得。 UC-II通过调节机体的免疫系统，起到改善关节活动性、灵活性和柔韧性，维持关节健康的作用。*
最新的随机，双盲，安慰剂对照临床研究表明，与安慰剂相比，UC-II®在改善关节功能，维护关节健康方面提供了显着效果*。
UC-II®与其他胶原蛋白的主要不同在于：
1. UC-II为非变性（天然）胶原蛋白：UC-II采用专利低温制造工艺，确保二型胶原蛋白的立体螺旋结构的完整性。这样的结构使得UC-II坚硬不易被肠道内的酸和蛋白酶破坏。UC-II是目前市场唯一的非变二型胶原蛋白。其它胶原蛋白大多为变性胶原蛋白，或为水解胶原蛋白。
2. 根据实验室和临床研究，制造商声称UC-II非变性胶原蛋白不同于水解或变性胶原蛋白，UC-II含有主动免疫调节剂，可以减少分解二型胶原蛋白的酶的分泌，从而减缓炎症反应。
2016年发表在美国“营养学杂志”上的一项研究将191名老年性骨性关节炎患者分为三组：一组为安慰剂对照组; 一组接受UC-II治疗，第三组接受盐酸氨基葡萄糖+硫酸软骨素补充剂（G+C）治疗。 经过治疗180天后，结果显示，UC-II组在改善关节疼痛、僵硬和恢复功能方面比安慰剂对照组和G+C治疗组表现出更好的效果。
UC-II对类风湿性关节炎患者进行的研究取得了令人振奋的结果。 2009年一项超过500名类风湿性关节炎患者的双盲试验发现，非变性胶原蛋白（UC-II）既改善了受试者的关节疼痛和晨僵，又减少了僵硬关节的数量和肿胀关节的数量。 这项发表于《关节炎研究和治疗》（Arthritis Research and Therapy）的研究论文得出结论：UC-II治疗类风湿性关节炎是安全有效的。
1. 长期、多次、小剂量口服非变性II型胶原蛋白可以通过调节肠道内的肠系膜淋巴结诱导机体产生口服免疫耐受作用。这有助于免疫系统关闭对关节软骨的攻击破坏的自身免疫损伤进程，使关节炎得到缓解和改善。每日口服少量UC-II既可以纠正针对关节软骨中II型胶原蛋白的错误攻击，调节身体的免疫力，以便它再次正常工作。*
2. UC-II对动物和人类进行了大量研究，包括在哈佛大学医学院进行的研究 - 所有这些研究表明，UC-II非变性II型鸡胶原蛋白有效地重新编程了免疫系统。促进关节健康，增加关节活动性和灵活性。*
3. UC-II通过刺激肠道内的调节性T细胞使其分泌转化生长因子β（TGF-β)和白细胞介素10（IL-10），这两种细胞因子参与关节内二型胶原的再生和关节修复过程。*
着名的Eurofins / Product产品安全实验室和美国莫瑞州立大学毒理系，休斯顿大学药学系多家医疗机构联合进行的产品安全性试验证实本产品长期服用无毒，无副作用。该研究检查了急性口服毒性，急性皮肤毒性，原发性皮肤和原发性眼睛刺激，Ames细菌反向突变试验。小鼠淋巴瘤试验和90天毒性试验。结果表明，当在雄性和雌性Sprague Dawley大鼠中口服施用时，UC-II的LD50大于5,000 mg / kg。在雄性和雌性大鼠中，UC-II的急性皮肤毒性大于2,000mg / kg。雄性和雌性新西兰白化兔的原发性皮肤刺激实验仅表现轻微刺激，并在24小时内消失。 UC-II在5种鼠伤寒沙门氏菌的Ames细菌回复突变试验中未诱导诱变效应。总之，这些结果证明了UC-II对动物和人类的广谱安全性。*
- * 本声明未经美国食品药品管理局评估。 本产品不用于诊断，治疗或预防任何疾病。 本网站提供的信息仅供您一般参考，不能代替专业医疗建议或针对特定疾病的治疗。
